Genmab — Februar 2019
-
Upon the expiration or loss of patent protection for a product, or upon the “at-risk” launch by a manufacturer of a generic version of one of our products, we can quickly lose a significant portion of our sales of that product. In addition, as additional competitors enter the market, our patented products may face increased competition or pricing pressure http://q4live.s22.clientfiles.s3-website-us-east-1.amazonaws.com/728481125/files/doc_financials/2018/b0b91209-0f73-447c-93ab-9027fb4c6bbf.pdf
-
Jeg læste et sted at generic Revlimid koster 1% af den originale ? Det må da også påvirke priserne i US, selvom det kun bliver markedsført i Europa ? https://www.npr.org/sections/health-shots/2018/05/17/571986468/how-a-drugmaker-gamed-the-system-to-keep-generic-competition-away?t=1550067479094
-
Det skal sgu nok ændre dynamikken i markedet!!!
-
-
-
-
ups wrong lınk. thıs ıs the one thats new: https://twitter.com/Sqwii/status/1095606637992251392
-
God morgen.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind